Mahmoud Al Rifai1, Xiaoming Jia2, Mouaz H Al-Mallah3, Michael D Miedema4, Seth S Martin5, Salim S Virani6,7,8. 1. Department of Medicine, University of Kansas School of Medicine, Wichita, KS, USA. 2. Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. Department of Cardiac Imaging, Houston Methodist Hospital, Houston, TX, USA. 4. Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. 5. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. 6. Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. virani@bcm.edu. 7. Health Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, 2002 Holcombe Boulevard, Houston, TX, 77030, USA. virani@bcm.edu. 8. Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. virani@bcm.edu.
Abstract
PURPOSE OF REVIEW: At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented. RECENT FINDINGS: The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk. The CREOLE trial compared three different combination antihypertensive therapies for blood pressure lowering among black individuals in sub-Saharan Africa. The INFINITY trial examined the effect of intensive blood pressure control on progression of brain white matter changes and various components of mobility and cognitive function. Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease. These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.
PURPOSE OF REVIEW: At the 2019 American College of Cardiology annual scientific sessions, major randomized clinical trials in cardiovascular disease (CVD) prevention were presented. RECENT FINDINGS: The CLEAR Wisdom trial examined the safety and efficacy of adding bempedoic acid to maximally tolerated statin for reducing low-density lipoprotein cholesterol. Post hoc analyses from the REDUCE-IT trial evaluated the efficacy of icosapent ethyl for lowering risk of total (first time and recurrent) CVD events. A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk. The CREOLE trial compared three different combination antihypertensive therapies for blood pressure lowering among black individuals in sub-Saharan Africa. The INFINITY trial examined the effect of intensive blood pressure control on progression of brain white matter changes and various components of mobility and cognitive function. Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease. These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.
Authors: Xiaoming Jia; Julia M Akeroyd; Khurram Nasir; Vijay Nambi; Christie M Ballantyne; Laura A Petersen; Salim S Virani Journal: Circulation Date: 2019-03-05 Impact factor: 29.690
Authors: Eri T Kato; Michael G Silverman; Ofri Mosenzon; Thomas A Zelniker; Avivit Cahn; Remo H M Furtado; Julia Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc P Bonaca; Christian T Ruff; Akshay S Desai; Shinya Goto; Peter A Johansson; Ingrid Gause-Nilsson; Per Johanson; Anna Maria Langkilde; Itamar Raz; Marc S Sabatine; Stephen D Wiviott Journal: Circulation Date: 2019-03-18 Impact factor: 29.690
Authors: Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher Journal: N Engl J Med Date: 2018-11-07 Impact factor: 91.245